Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 14500340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms.

  2002cited by this paper
• Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

  2002cited by this paper
• BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

  2002cited by this paper
• Endocrine gland–derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis

  2002cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002influential reference
• Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin

  2002cited by this paper
• Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

  2002cited by this paper
• TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

  2002cited by this paper
• How oxygen makes its presence felt.

  2002influential reference
• A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.

  2002influential reference
• Hypoxia — a key regulatory factor in tumour growth

  2002influential reference
• Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

  2002cited by this paper
• Involvement of hypoxia-inducible factor 1 in human cancer.

  2002influential reference
• Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.

  2001cited by this paper
• Molecular genetic advances in tuberous sclerosis

  2000cited by this paper
• Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background.

  1999cited by this paper
• Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.

  1998cited by this paper
• Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles.

  1998cited by this paper
• V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.

  1997cited by this paper

• TSC2 is a positive master regulator of cellulase production by affecting protein secretion in Trichoderma reesei.

  2025cites this paper
• Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex

  2023cites this paper
• Advances in the study of exosomes in cardiovascular diseases

  2023cites this paper
• Dysregulation of Acid Ceramidase-mediated Sphingolipid Metabolism Contributes to Tumor Progression in Tuberous Sclerosis Complex

  2022cites this paper
• Peripheral Serum Exosomes Isolated from Patients with Acute Myocardial Infarction Promote Endothelial Cell Angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α Pathway

  2022cites this paper
• New imaging features of tuberous sclerosis complex: A 7 T MRI study

  2021cites this paper
• Synthetic mRNAs; Their Analogue Caps and Contribution to Disease

  2021cites this paper
• Anticancer potential of metformin: focusing on gastrointestinal cancers

  2021cites this paper
• Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex

  2020cites this paper
• Shuxuening injection, derived from Ginkgo biloba leaf, induced pseudo-allergic reactions through hyperactivation of mTOR

  2020cites this paper
• Hereditary renal cell carcinoma syndromes

  2020cites this paper
• Congenital Limb Overgrowth Syndromes Associated with Vascular Anomalies.

  2019cites this paper
• Changes in vascular density in resected tissue of 97 patients with mild malformation of cortical development, focal cortical dysplasia or TSC‐related cortical tubers

  2019cites this paper
• Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion

  2019cites this paper
• Hypervascularization in mTOR‐dependent focal and global cortical malformations displays differential rapamycin sensitivity

  2019cites this paper
• Overgrowth Syndromes Associated With Vascular Anomalies.

  2019cites this paper
• Structure and functions of the translation initiation factor eIF4E and its role in cancer development and treatment.

  2018cites this paper
• Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2

  2017cites this paper
• Tuberous sclerosis is an inherited tumour syndrome caused by mutations in TSC1 or TSC2 that lead to aberrant activation of mTOR and development of tumours in multiple organs

  2017cites this paper
• Cardiovascular considerations in tuberous sclerosis

  2017influential citation
• Therapeutic Potential of Everolimus on Core Autism Symptoms andIncreasing Serum Ceruloplasmin and Transferrin Levels in a PubescentBoy with Tuberous Sclerosis

  2017cites this paper
• Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+/− Mice Is Superior to Everolimus Alone

  2017cites this paper
• New Indications of mTOR Inhibitors in Rare Tumors

  2016cites this paper
• Hypoxia-inducible factor-1a contributes to dendritic overgrowth in tuberous sclerosis.

  2016cites this paper
• Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.

  2016cites this paper
• Combination of everolimus with sorafenib for solid renal tumours in Tsc2 mice is superior to everolimus alone Authors and affiliations:

  2016cites this paper
• Tuberous sclerosis complex

  2016cites this paper
• New trends in renal angiomyolipomas therapy

  2015cites this paper
• Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling.

  2015cites this paper
• Nové trendy v léčbě renálního angiomyolipomu

  2015cites this paper
• Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis*

  2015cites this paper
• Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer

  2015cites this paper
• The potential role of HIF on tumour progression and dissemination

  2015cites this paper
• Virus interactions with endothelial cell receptors: implications for viral pathogenesis.

  2014cites this paper
• Proteinuria and Everolimus. The Relevance of Knowing Urinary Sodium Excretion in a Kidney Transplant Patient

  2014cites this paper
• Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis

  2014cites this paper
• Somatic forward (nonrevertant) mosaicism in recessive dystrophic epidermolysis bullosa.

  2014cites this paper
• Molecular Mechanisms and Therapeutics of Skin Hamartomas in Tuberous Sclerosis Complex

  2014cites this paper
• Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.

  2014cites this paper
• A Case of Lymphangioleiomyomatosis with Hemorrhage in Retroperitoneal Space

  2014cites this paper
• A Vascular Model of Tsc1 Deficiency Accelerates Renal Tumor Formation with Accompanying Hemangiosarcomas

  2014cites this paper
• Hypoxia Induces Permeability and Giant Cell Responses of Andes Virus-Infected Pulmonary Endothelial Cells by Activating the mTOR-S6K Signaling Pathway

  2013cites this paper
• Hypoxia-inducible factor 1 a is a Tsc 1-regulated survival factor in newborn neurons in tuberous sclerosis complex

  2013cites this paper
• Characterising the tumour suppression function of folliculin

  2013cites this paper
• mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development

  2013cites this paper
• A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.

  2013cites this paper
• Role of Vascular and Lymphatic Endothelial Cells in Hantavirus Pulmonary Syndrome Suggests Targeted Therapeutic Approaches

  2013cites this paper
• Targeting the mTOR signalling pathway for prevention and therapy of tuberous sclerosis in mouse models

  2013cites this paper
• Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates

  2013cites this paper
• Myxoid liposarcoma and the mammalian target of rapamycin pathway

  2013cites this paper
• Hypoxia-inducible factor 1a is a Tsc1-regulated survival factor in newborn neurons in tuberous sclerosis complex.

  2013cites this paper
• Tumor progression and metastasis: role of translational deregulation.

  2012cites this paper
• Pharmacotherapy of Age-Related Macular Degeneration

  2012cites this paper
• An Elaborate Regulation of Mammalian Target of Rapamycin Activity Is Required for Somatic Cell Reprogramming Induced by Defined Transcription Factors

  2012cites this paper
• Targeting the intragraft microenvironment and the development of chronic allograft rejection.

  2012cites this paper
• The promise of mTOR inhibitors in the treatment of colorectal cancer

  2012cites this paper
• Transcatheter arterial embolization as therapy of renal angiomyolipomas: the evolution in 15 years of experience.

  2012cites this paper
• Expression and Cellular Distribution of Vascular Endothelial Growth Factor‐C System in Cortical Tubers of the Tuberous Sclerosis Complex

  2012cites this paper
• Constitutive activation of the mTOR signaling pathway within the normal glomerulus.

  2012cites this paper
• Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

  2011cites this paper
• Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

  2011cites this paper
• The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling

  2011cites this paper
• Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

  2011cites this paper
• Are port wines stains a feature of tuberous sclerosis?

  2011cites this paper
• Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.

  2011cites this paper
• Pulmonary Hypertension in Patients With Neurofibromatosis Type I

  2011cites this paper
• Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease

  2011cites this paper
• Tuberous sclerosis complex : clinical diagnostic criteria by Roach et al . [ 19 ]

  2011cites this paper
• Preclinical Development Ridaforolimus ( AP 23573 ; MK-8669 ) , a Potent mTOR Inhibitor , Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

  2011cites this paper
• Tuberous sclerosis complex: tumors and tumorigenesis

  2011cites this paper
• Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma.

  2011cites this paper
• The tuberous sclerosis complex

  2010cites this paper
• Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate.

  2010cites this paper
• Animal Models of Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)

  2010cites this paper
• Rat and Mouse Models of Tuberous Sclerosis

  2010cites this paper
• Lymphangioleiomyomatosis and TSC2-/- Cells

  2010cites this paper
• Renal Manifestations of Tuberous Sclerosis Complex

  2010cites this paper
• Molecular Cancer esearch aling and Regulation Serine Protease HtrA 1 Specifically Interacts and R rades the Tuberous Sclerosis Complex 2 Protein

  2010cites this paper
• The Serine Protease HtrA1 Specifically Interacts and Degrades the Tuberous Sclerosis Complex 2 Protein

  2010cites this paper
• mTORC1-S6K Activation by Endotoxin Contributes to Cytokine Up-Regulation and Early Lethality in Animals

  2010cites this paper
• VHL and HIF signalling in renal cell carcinogenesis

  2010cites this paper
• Cutaneous T‐cell lymphoma cells are sensitive to rapamycin

  2010cites this paper
• The Role of Target of Rapamycin Signaling in Tuberous Sclerosis Complex

  2010cites this paper
• A comprehensive map of the mTOR signaling network

  2010cites this paper
• Dysregulation of TOR Signaling in Tuberous Sclerosis and Lymphangioleiomyomotosis

  2010cites this paper
• mTOR signaling and drug development in cancer

  2010cites this paper
• Pi3K‐mTOR Signaling and AMOG Expression in Epilepsy‐associated Glioneuronal Tumors

  2010cites this paper
• Angiogenesis in cutaneous disease: part II.

  2009influential citation
• Title Angiogenesis in cutaneous disease : Part II Permalink

  2009influential citation
• Angiogenesis in cutaneous disease: part I.

  2009cites this paper
• Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.

  2009cites this paper
• Molecular alterations in epilepsy-associated malformations of cortical development

  2009cites this paper
• Bone growth during rapamycin therapy in young rats

  2009cites this paper
• Tuberous Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27 Kip1 Localization Cell, Tumor, and Stem Cell Biology

  2009cites this paper
• Molecular pathways involved in hair follicle tumor formation: all about mammalian target of rapamycin?

  2009cites this paper
• Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis

  2009cites this paper
• Renal involvement in tuberous sclerosis complex and von Hippel–Lindau disease: shared disease mechanisms?

  2009cites this paper
• The role of mTOR in the management of solid tumors: an overview.

  2009cites this paper
• Perfusion Abnormalities in Hemimegalencephaly

  2009cites this paper
• Recent perspectives on diagnosis and treatment of tuberous sclerosis complex in children

  2009cites this paper